These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26837761)

  • 1. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
    McGrath JP; Williamson KE; Balasubramanian S; Odate S; Arora S; Hatton C; Edwards TM; O'Brien T; Magnuson S; Stokoe D; Daniels DL; Bryant BM; Trojer P
    Cancer Res; 2016 Apr; 76(7):1975-88. PubMed ID: 26837761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
    Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
    Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
    Jiang Q; Stachelscheid J; Bloehdorn J; Pacholewska A; Aszyk C; Grotenhuijs F; Müller T; Onder O; Wagle P; Herling CD; Kleppe M; Wang Z; Coombes KR; Robrecht S; Dalvi PS; Plosnita B; Mayer P; Abruzzo LV; Altmüller J; Gathof B; Persigehl T; Fischer K; Jebaraj B; Rienhoff HY; Ecker R; Zhao Y; Bruns CJ; Stilgenbauer S; Elenitoba-Johnson K; Hallek M; Schweiger MR; Odenthal M; Vasyutina E; Herling M
    Blood; 2023 Jul; 142(1):44-61. PubMed ID: 37023372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A microenvironment, its oncogenic potential, and therapeutic significance.
    Ismail T; Lee HK; Kim C; Kwon T; Park TJ; Lee HS
    Epigenetics Chromatin; 2018 Jun; 11(1):33. PubMed ID: 29921310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
    Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
    Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.
    Nagasaka M; Tsuzuki K; Ozeki Y; Tokugawa M; Ohoka N; Inoue Y; Hayashi H
    Biol Pharm Bull; 2019; 42(3):481-488. PubMed ID: 30828079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship.
    Vianello P; Sartori L; Amigoni F; Cappa A; Fagá G; Fattori R; Legnaghi E; Ciossani G; Mattevi A; Meroni G; Moretti L; Cecatiello V; Pasqualato S; Romussi A; Thaler F; Trifiró P; Villa M; Botrugno OA; Dessanti P; Minucci S; Vultaggio S; Zagarrí E; Varasi M; Mercurio C
    J Med Chem; 2017 Mar; 60(5):1693-1715. PubMed ID: 28186757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.
    Chen M; Zhu N; Liu X; Laurent B; Tang Z; Eng R; Shi Y; Armstrong SA; Roeder RG
    Genes Dev; 2015 Oct; 29(20):2123-39. PubMed ID: 26494788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline Lysine-Specific Demethylase 1 (
    Wei X; Calvo-Vidal MN; Chen S; Wu G; Revuelta MV; Sun J; Zhang J; Walsh MF; Nichols KE; Joseph V; Snyder C; Vachon CM; McKay JD; Wang SP; Jayabalan DS; Jacobs LM; Becirovic D; Waller RG; Artomov M; Viale A; Patel J; Phillip J; Chen-Kiang S; Curtin K; Salama M; Atanackovic D; Niesvizky R; Landgren O; Slager SL; Godley LA; Churpek J; Garber JE; Anderson KC; Daly MJ; Roeder RG; Dumontet C; Lynch HT; Mullighan CG; Camp NJ; Offit K; Klein RJ; Yu H; Cerchietti L; Lipkin SM
    Cancer Res; 2018 May; 78(10):2747-2759. PubMed ID: 29559475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
    Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P
    Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
    Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
    Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
    Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
    J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A.
    Yang H; Li Q; Zhao W; Yuan D; Zhao H; Zhou Y
    FEBS Lett; 2014 Jan; 588(1):192-7. PubMed ID: 24316513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rationally-designed chimeric KDM1A/KDM1B histone demethylase tower domain deletion mutant retaining enzymatic activity.
    Burg JM; Makhoul AT; Pemble CW; Link JE; Heller FJ; McCafferty DG
    FEBS Lett; 2015 Aug; 589(18):2340-6. PubMed ID: 26226427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone demethylase KDM1A is essential for the maintenance and differentiation of spermatogonial stem cells and progenitors.
    Lambrot R; Lafleur C; Kimmins S
    FASEB J; 2015 Nov; 29(11):4402-16. PubMed ID: 26243864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
    Pajtler KW; Weingarten C; Thor T; Künkele A; Heukamp LC; Büttner R; Suzuki T; Miyata N; Grotzer M; Rieb A; Sprüssel A; Eggert A; Schramm A; Schulte JH
    Acta Neuropathol Commun; 2013 May; 1():19. PubMed ID: 24252778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone demethylase KDM1A represses inflammatory gene expression in preadipocytes.
    Hanzu FA; Musri MM; Sánchez-Herrero A; Claret M; Esteban Y; Kaliman P; Gomis R; Párrizas M
    Obesity (Silver Spring); 2013 Dec; 21(12):E616-25. PubMed ID: 23595969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.